223 related articles for article (PubMed ID: 31768386)
1. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Suzuki Y; Watanabe M; Matsui T; Motoya S; Hisamatsu T; Yuasa H; Tabira J; Isogawa N; Tsuchiwata S; Arai S; Hibi T
Inflamm Intest Dis; 2019 Oct; 4(4):131-143. PubMed ID: 31768386
[TBL] [Abstract][Full Text] [Related]
2. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Motoya S; Watanabe M; Kim HJ; Kim YH; Han DS; Yuasa H; Tabira J; Isogawa N; Arai S; Kawaguchi I; Hibi T
Intest Res; 2018 Apr; 16(2):233-245. PubMed ID: 29743836
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
[TBL] [Abstract][Full Text] [Related]
6. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.
Vavricka SR; Greuter T; Cohen BL; Reinisch W; Steinwurz F; Fellmann M; Guo X; Lawendy N; Paulissen J; Peyrin-Biroulet L
Therap Adv Gastroenterol; 2022; 15():17562848221090834. PubMed ID: 35574426
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
[TBL] [Abstract][Full Text] [Related]
9. Modified Mayo score
Sandborn WJ; Sands BE; Vermeire S; Leung Y; Guo X; Modesto I; Su C; Wang W; Panés J
Therap Adv Gastroenterol; 2022; 15():17562848221136331. PubMed ID: 36506749
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
12. Presence of risk factors associated with colectomy among patients with ulcerative colitis: a
Rubin DT; Salese L; Cohen M; Kotze PG; Woolcott JC; Su C; Mundayat R; Paulissen J; Torres J; Long MD
Therap Adv Gastroenterol; 2023; 16():17562848231189122. PubMed ID: 37560161
[TBL] [Abstract][Full Text] [Related]
13. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
Rubin DT; Reinisch W; Greuter T; Kotze PG; Pinheiro M; Mundayat R; Maller E; Fellmann M; Lawendy N; Modesto I; Vavricka SR; Lichtenstein GR
Therap Adv Gastroenterol; 2021; 14():17562848211005708. PubMed ID: 34035832
[TBL] [Abstract][Full Text] [Related]
14. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
15. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR; Gecse KB; Chiorean MV; Argollo M; Guo X; Lawendy N; Su C; Mundayat R; Paulissen J; Salese L; Irving PM
J Gastroenterol Hepatol; 2024 Feb; 39(2):264-271. PubMed ID: 37953548
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Hanauer S; Panaccione R; Danese S; Cheifetz A; Reinisch W; Higgins PDR; Woodworth DA; Zhang H; Friedman GS; Lawendy N; Quirk D; Nduaka CI; Su C
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):139-147. PubMed ID: 30012431
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Sandborn WJ; Armuzzi A; Liguori G; Irving PM; Sharara AI; Mundayat R; Lawendy N; Woolcott JC; Danese S
Inflamm Bowel Dis; 2022 Sep; 28(9):1338-1347. PubMed ID: 34958359
[TBL] [Abstract][Full Text] [Related]
20. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
